Prognostic effects of benidipine in patients with vasospastic angina: comparison with diltiazem and amlo- dipine. J Cardiovasc Pharmacol. 2008;51:253 7. 757. Kimura E, Kishida H. Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. Circulation. 1981;63:844 8. 758. Kugiyama K, Ohgushi M, Sugiyama S, et al. Supersensitive dilator response to nitroglycerin but not to atrial natriuretic peptide in spastic cor- onary arteries in coronary spastic angina. Am J Cardiol. 1997;79:606 10. 759. Tani S, Nagao K, Anazawa T, et al. Treatment of coronary spastic angina with a statin in addition to a calcium channel blocker: a pilot study. J Cardiovasc Pharmacol. 2008;52:28 34. 760. Yasue H, Mizuno Y, Harada E, et al. Effects of a 3-hydroxy-3-meth- ylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers. J Am Coll Cardiol. 2008;51:1742 8. 761. Sugiishi M, Takatsu F. Cigarette smoking is a major risk factor for coro- nary spasm. Circulation. 1993;87:76 9. 762. Nobuyoshi M, Abe M, Nosaka H, et al. Statistical analysis of clinical risk factors for coronary artery spasm: identification of the most important determinant. Am Heart J. 1992;124:32 8. 763. Yamagishi M, Ito K, Tsutsui H, et al. Lesion severity and hypercholester- olemia determine long-term prognosis of vasospastic angina treated with calcium channel antagonists. Circ J. 2003;67:1029 35. 764. Koizumi T,Yokoyama M, Namikawa S, et al. Location of focal vasospasm provoked by ergonovine maleate within coronary arteries in patients with vasospastic angina pectoris. Am J Cardiol. 2006;97:1322 5. 765. Ong P, Athanasiadis A, Hill S, et al. Coronary artery spasm as a frequent cause of acute coronary syndrome: The CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) Study. J Am Coll Cardiol. 2008;52:523 7. 766. Cheng CW,Yang NI, Lin KJ, et al. 